Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.56 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037184 | 1.00 | PARP1 (0.56) | PARP1HTR3BADRA2AKCNE1ADRA2C | |
| Hydrochloric Acid SCHEMBL2456613 | 0.98 | PARP1 (0.55) | PARP1HTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL21556355 | 0.81 | HTR3B (0.40) | PARP1HTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL19698078 | 0.81 | HTR3B (0.40) | PARP1HTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4501455 | 0.77 | OPRL1 (0.35) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL3586036 | 0.76 | HTR3B (0.48) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL830902 | 0.76 | HTR3B (0.48) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL7013965 | 0.76 | HTR3B (0.48) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL25138070 | 0.74 | PARP1 (0.51) | PARP1HTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL829382 | 0.74 | HTR3B (0.50) | HTR3BADRA2AKCNE1ADRA2CCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381198-A1 | MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-12-18 | — | — | US | disclosed |
| US-12083126-B2 | Pharmaceutical compositions and methods for anesthesiological applications | MELT PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240207285-A1 | MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2024-06-27 | — | — | US | disclosed |
| US-20220249510-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2022-08-11 | — | — | US | disclosed |
| EP-4019023-A1 | FORMULATIONS OF FOSAPREPITANT AND APREPITANT | Zhuhai Beihai Biotech Co., Ltd. (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022038528-A1 | NANO LIPID CARRIER SYSTEM FOR IMPROVING PERMEATION OF ACTIVE INGREDIENTS | LEIUTIS PHARMACEUTICALS LLP (IN) | 2022-02-24 | — | — | WO | disclosed |
| US-20210085691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2021-03-25 | — | — | US | disclosed |
| US-20200297734-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2020-09-24 | — | — | US | disclosed |
| US-20200155568-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2020-05-21 | — | — | US | disclosed |
| US-10391102-B2 | Pharmaceutical compositions and methods for anesthesiological applications | MELT PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180177797-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2018-06-28 | — | — | US | disclosed |
| WO-2018094394-A1 | FORMULATIONS OF ROLAPITANT | ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) | 2018-05-24 | — | — | WO | disclosed |
| US-9918993-B2 | Pharmaceutical compositions for anesthesiological applications | IMPRIMIS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| WO-2018027029-A1 | FORMULATIONS OF FOSAPREPITANT AND APREPITANT | ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) | 2018-02-08 | — | — | WO | disclosed |
| US-20160367566-A1 | PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2016-12-22 | — | — | US | disclosed |
| US-20120253046-A1 | PALONOSETRON METABOLITES | HELSINN HEALTHCARE S.A. (CH) | 2012-10-04 | — | — | US | disclosed |
| US-8093391-B2 | Process for the preparation of substantially pure palonosetron and its acid salts | Sterling Biotech Research Center (IN) | 2012-01-10 | — | — | US | disclosed |
| US-20110021778-A1 | Process for the Preparation of Substantially Pure Palonosetron and its Acid Salts | STERLING BIOTECH RESEARCH CENTER, A CORPORATE RESEARCH CENTER OF STERLING BIOTECH LTD. (IN) | 2011-01-27 | — | — | US | disclosed |
| US-20070059254-A1 | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | TRANSORAL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070059254-A1 | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | TRANSORAL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249510-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN3A, OPRK1, GRIN2B | PARP1 3797/4885HTR3B 266/4885ADRA2A 61/4885 |
| US-20180177797-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN2B, GRIN3A, GABRA5 | PARP1 3568/4885HTR3B 269/4885ADRA2A 83/4885 |
| US-10391102-B2 | Pharmaceutical compositions and methods for anesthesiological applications | GRIN2B, GRIN3A, GABRA5 | PARP1 3568/4885HTR3B 269/4885ADRA2A 84/4885 |
| US-20240207285-A1 | MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION | KCNA3, OPRK1, KCNA7 | PARP1 3585/4885HTR3B 131/4885ADRA2A 52/4885 |
| US-20160367566-A1 | PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN2B, GRIN3A, GABRB1 | PARP1 3210/4885HTR3B 262/4885ADRA2A 90/4885 |
| US-20200297734-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN3A, OPRK1, GRIN2B | PARP1 3797/4885HTR3B 266/4885ADRA2A 61/4885 |
| US-20210085691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN2B, GRIN3A, GRIN1 | PARP1 3256/4885HTR3B 227/4885ADRA2A 76/4885 |
| US-20250381198-A1 | MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION | KCNA3, OPRK1, KCNA7 | PARP1 3585/4885HTR3B 131/4885ADRA2A 52/4885 |
| US-20200155568-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN2B, GRIN3A, GABRA5 | PARP1 3568/4885HTR3B 269/4885ADRA2A 84/4885 |
| US-20120253046-A1 | PALONOSETRON METABOLITES | CYP3A5, MC2R, CYP21A2 | PARP1 2007/4885HTR3B 168/4885ADRA2A 325/4885 |
| US-20070059254-A1 | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | HTR5A, HTR1A, HTR3A | PARP1 3336/4885HTR3B 6/4885ADRA2A 442/4885 |
| US-12083126-B2 | Pharmaceutical compositions and methods for anesthesiological applications | GRIN3A, OPRK1, GRIN2B | PARP1 3797/4885HTR3B 266/4885ADRA2A 61/4885 |
| US-20110021778-A1 | Process for the Preparation of Substantially Pure Palonosetron and its Acid Salts | CYP21A2, CYP26B1, CYP26A1 | PARP1 1889/4885HTR3B 36/4885ADRA2A 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.